Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 24924991

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2014 Jul
First author
Vora A

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2014 Jul;15(8):777-8. doi: 10.1016/S1470-2045(14)70280-3.
    note
    Source null
    related pmid
    24924992
    relationship
    Comment in

Authors and identifiers

  1. name
    Vora A
    type
    Author
  2. name
    Goulden N
    type
    Author
  3. name
    Mitchell C
    type
    Author
  4. name
    Hancock J
    type
    Author
  5. name
    Hough R
    type
    Author
  6. name
    Rowntree C
    type
    Author
  7. name
    Moorman AV
    type
    Author
  8. name
    Wade R
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Vora A
    type
    Author
  2. name
    Goulden N
    type
    Author
  3. name
    Mitchell C
    type
    Author
  4. name
    Hancock J
    type
    Author
  5. name
    Hough R
    type
    Author
  6. name
    Rowntree C
    type
    Author
  7. name
    Moorman AV
    type
    Author
  8. name
    Wade R
    type
    Author
bibliography ids
  1. nci-bib-2207f4735f32be442ad86c8a
book metadata
content sha256
cf3d27865af1882569dd318068c0ad052835c315aa701837bfa0b332d61e96b5
document type
citation
dois
  1. 10.1016/S1470-2045(14)70243-8
electronic publication date
display
2014 Jun 9
precision
day
year
2014
evidence scope
bibliographic_metadata_only
id
pubmed:24924991
immutable id
pubmed:24924991@cf3d27865af1882569dd318068c0ad052835c315aa701837bfa0b332d61e96b5
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
8
name
The Lancet. Oncology
nlm unique id
100957246
pages
809-18
volume
15
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2014 Jul;15(8):777-8. doi: 10.1016/S1470-2045(14)70280-3.
    note
    Source null
    related pmid
    24924992
    relationship
    Comment in
outcomes validated
false
pmid
24924991
provenance
batch id
69903be8ceab8801c81a
provider
NCBI PubMed ESummary
record sha256
f1631f55b4b6f94c3799e18f7ebfdb656382770cb9d9ab28a3763cfa6787c9a1
response sha256
1e367491c3c459a93f45b3db99ca1f9293ed2287c48bdf758bb088ffcd7c96eb
retrieved at
2026-09-09T23:47:05.208886+00:00
publication date
display
2014 Jul
precision
month
year
2014
publication types
  1. Journal Article
  2. Randomized Controlled Trial
  3. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/24924991/
title
Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.

Preserved source evidence · Not medical advice